These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Bostrom J; Yu SF; Kan D; Appleton BA; Lee CV; Billeci K; Man W; Peale F; Ross S; Wiesmann C; Fuh G Science; 2009 Mar; 323(5921):1610-4. PubMed ID: 19299620 [TBL] [Abstract][Full Text] [Related]
4. An antibody which behaves like a man with a wife and a mistress. Griffiths PD Rev Med Virol; 2009 Jul; 19(4):181-3. PubMed ID: 19530116 [No Abstract] [Full Text] [Related]
5. A revival of bispecific antibodies. Kufer P; Lutterbüse R; Baeuerle PA Trends Biotechnol; 2004 May; 22(5):238-44. PubMed ID: 15109810 [No Abstract] [Full Text] [Related]
6. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies. Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564 [TBL] [Abstract][Full Text] [Related]
7. Phase I trial of 2B1, a bispecific monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. Weiner LM; Clark JI; Davey M; Li WS; Garcia de Palazzo I; Ring DB; Alpaugh RK Cancer Res; 1995 Oct; 55(20):4586-93. PubMed ID: 7553634 [TBL] [Abstract][Full Text] [Related]
8. A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Schaefer G; Haber L; Crocker LM; Shia S; Shao L; Dowbenko D; Totpal K; Wong A; Lee CV; Stawicki S; Clark R; Fields C; Lewis Phillips GD; Prell RA; Danilenko DM; Franke Y; Stephan JP; Hwang J; Wu Y; Bostrom J; Sliwkowski MX; Fuh G; Eigenbrot C Cancer Cell; 2011 Oct; 20(4):472-86. PubMed ID: 22014573 [TBL] [Abstract][Full Text] [Related]
9. Smarter drugs: a focus on pan-specific monoclonal antibodies. Fagète S; Fischer N BioDrugs; 2011 Dec; 25(6):357-64. PubMed ID: 22050338 [TBL] [Abstract][Full Text] [Related]
10. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting. Gu J; Ghayur T Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980 [TBL] [Abstract][Full Text] [Related]
11. Conformational changes in a Vernier zone region: Implications for antibody dual specificity. Arslan M; Karadag D; Kalyoncu S Proteins; 2020 Nov; 88(11):1447-1457. PubMed ID: 32526069 [TBL] [Abstract][Full Text] [Related]
12. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. Chen Y; Wiesmann C; Fuh G; Li B; Christinger HW; McKay P; de Vos AM; Lowman HB J Mol Biol; 1999 Nov; 293(4):865-81. PubMed ID: 10543973 [TBL] [Abstract][Full Text] [Related]
13. Monoclonal antibody therapeutics with up to five specificities: functional enhancement through fusion of target-specific peptides. LaFleur DW; Abramyan D; Kanakaraj P; Smith RG; Shah RR; Wang G; Yao XT; Kankanala S; Boyd E; Zaritskaya L; Nam V; Puffer BA; Buasen P; Kaithamana S; Burnette AF; Krishnamurthy R; Patel D; Roschke VV; Kiener PA; Hilbert DM; Barbas CF MAbs; 2013; 5(2):208-18. PubMed ID: 23575268 [TBL] [Abstract][Full Text] [Related]
14. [Antibody-conjugated cytostatic drugs. Uses of monoclonal antibodies for new strategies in tumor therapy]. Renner C; Pfreundschuh M Fortschr Med; 1994 Oct; 112(29):399. PubMed ID: 8001887 [No Abstract] [Full Text] [Related]
15. Expression and purification of monospecific and bispecific recombinant antibody fragments derived from antibodies that block the CD80/CD86-CD28 costimulatory pathway. Dincq S; Bosman F; Buyse MA; Degrieck R; Celis L; de Boer M; Van Doorsselaere V; Sablon E Protein Expr Purif; 2001 Jun; 22(1):11-24. PubMed ID: 11388794 [TBL] [Abstract][Full Text] [Related]
16. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Cho HS; Mason K; Ramyar KX; Stanley AM; Gabelli SB; Denney DW; Leahy DJ Nature; 2003 Feb; 421(6924):756-60. PubMed ID: 12610629 [TBL] [Abstract][Full Text] [Related]
17. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Spiridon CI; Ghetie MA; Uhr J; Marches R; Li JL; Shen GL; Vitetta ES Clin Cancer Res; 2002 Jun; 8(6):1720-30. PubMed ID: 12060609 [TBL] [Abstract][Full Text] [Related]